Akebia Therapeutics (AKBA) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $0.67, -3.74% vs the prior close of $0.70.
- Volume 7.05M shares, 0.9x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
AKBA slides 3.7% to $0.67, a 52-week low, 9 down days in a row. Closed at $0.67, -3.74% vs the prior close of $0.70. Day range $0.67–$0.73, opened at $0.71.
AKBA daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — AKBA slides 3.7% to $0.67, a 52-week low, 9 down days in a row
- Closed at $0.67, -3.74% vs the prior close of $0.70. Day range $0.67–$0.73, opened at $0.71.
- Volume was 7.05M shares, 0.9x its 50-day average of 7.84M.
- Price is -24.8% vs its 50-day average ($0.89) and -43.6% vs its 200-day average ($1.19).
- 52-week range $0.67–$3.20; today's close sits at 0% of that range, 79.1% below the 52-week high.
- That makes 9 straight losses.
Oct 15, 2026 — AKBA dips 0.9% to $0.70, a 52-week low, 8 down days in a row
- Closed at $0.70, -0.85% vs the prior close of $0.70. Day range $0.69–$0.73, opened at $0.70.
- Volume was 8.85M shares, 1.1x its 50-day average of 7.75M.
- Price is -22.4% vs its 50-day average ($0.90) and -41.7% vs its 200-day average ($1.19).
- 52-week range $0.69–$3.20; today's close sits at 0% of that range, 78.3% below the 52-week high.
- That makes 8 straight losses.
Oct 14, 2026 — AKBA slides 8.8% to $0.70, a 52-week low on 1.9x normal volume
- Closed at $0.70, -8.83% vs the prior close of $0.77. Day range $0.70–$0.77, opened at $0.75.
- Volume was 13.96M shares, 1.9x its 50-day average of 7.53M — unusually heavy trading.
- Price is -22.7% vs its 50-day average ($0.91) and -41.4% vs its 200-day average ($1.20).
- 52-week range $0.70–$3.20; today's close sits at 0% of that range, 78.1% below the 52-week high.
- That makes 7 straight losses.
- SEC filings that day: 8-K.
Oct 13, 2026 — AKBA dips 2.5% to $0.77, a 52-week low, 6 down days in a row
- Closed at $0.77, -2.53% vs the prior close of $0.79. Day range $0.77–$0.81, opened at $0.80.
- Volume was 6.50M shares, 0.9x its 50-day average of 7.44M.
- Price is -16.4% vs its 50-day average ($0.92) and -36.0% vs its 200-day average ($1.20).
- 52-week range $0.77–$3.20; today's close sits at 0% of that range, 75.9% below the 52-week high.
- That makes 6 straight losses.
Oct 12, 2026 — AKBA dips 1.4% to $0.79, a 52-week low, 5 down days in a row
- Closed at $0.79, -1.37% vs the prior close of $0.80. Day range $0.77–$0.81, opened at $0.80.
- Volume was 8.87M shares, 1.2x its 50-day average of 7.30M.
- Price is -15.2% vs its 50-day average ($0.93) and -34.6% vs its 200-day average ($1.21).
- 52-week range $0.77–$3.20; today's close sits at 1% of that range, 75.3% below the 52-week high.
- That makes 5 straight losses.
Oct 9, 2026 — AKBA dips 1.7% to $0.80, a 52-week low, 4 down days in a row
- Closed at $0.80, -1.72% vs the prior close of $0.81. Day range $0.80–$0.83, opened at $0.82.
- Volume was 6.09M shares, 0.8x its 50-day average of 7.24M.
- Price is -15.0% vs its 50-day average ($0.94) and -33.9% vs its 200-day average ($1.21).
- 52-week range $0.80–$3.20; today's close sits at 0% of that range, 75.0% below the 52-week high.
- That makes 4 straight losses.
Oct 8, 2026 — AKBA slides 6.6% to $0.81, a 52-week low, 3 down days in a row
- Closed at $0.81, -6.64% vs the prior close of $0.87. Day range $0.81–$0.87, opened at $0.85.
- Volume was 7.45M shares, 1.0x its 50-day average of 7.13M.
- Price is -14.5% vs its 50-day average ($0.95) and -33.0% vs its 200-day average ($1.22).
- 52-week range $0.81–$3.20; today's close sits at 0% of that range, 74.5% below the 52-week high.
- That makes 3 straight losses.
Oct 7, 2026 — AKBA dips 0.7% to $0.87
- Closed at $0.87, -0.68% vs the prior close of $0.88. Day range $0.86–$0.89, opened at $0.86.
- Volume was 9.16M shares, 1.3x its 50-day average of 6.98M.
- Price is -9.3% vs its 50-day average ($0.96) and -28.4% vs its 200-day average ($1.22).
- 52-week range $0.81–$3.20; today's close sits at 2% of that range, 72.7% below the 52-week high.
Oct 6, 2026 — AKBA slides 3.5% to $0.88
- Closed at $0.88, -3.51% vs the prior close of $0.91. Day range $0.88–$0.91, opened at $0.90.
- Volume was 6.18M shares, 0.9x its 50-day average of 6.90M.
- Price is -9.4% vs its 50-day average ($0.97) and -28.2% vs its 200-day average ($1.22).
- 52-week range $0.81–$3.20; today's close sits at 3% of that range, 72.5% below the 52-week high.
Oct 5, 2026 — AKBA jumps 5.3% to $0.91
- Closed at $0.91, +5.32% vs the prior close of $0.87. Day range $0.85–$0.92, opened at $0.87.
- Volume was 7.50M shares, 1.1x its 50-day average of 6.78M.
- Price is -6.9% vs its 50-day average ($0.98) and -25.8% vs its 200-day average ($1.23).
- 52-week range $0.81–$3.20; today's close sits at 4% of that range, 71.5% below the 52-week high.
Oct 2, 2026 — AKBA dips 0.7% to $0.87, a 1-month low
- Closed at $0.87, -0.69% vs the prior close of $0.87. Day range $0.84–$0.89, opened at $0.89.
- Volume was 7.11M shares, 1.1x its 50-day average of 6.67M.
- Price is -12.1% vs its 50-day average ($0.98) and -29.7% vs its 200-day average ($1.23).
- 52-week range $0.81–$3.20; today's close sits at 2% of that range, 73.0% below the 52-week high.
AKBA latest news & SEC filings
Every SEC filing by or about AKBA in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 14, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Aug 10, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 5, 2026 · Form S-8 — Employee share plan registration
Registration of shares for employee stock plans (S-8)
Aug 5, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $49.13M (prior year $62.47M) (-21.4% vs Jun 30, 2025)
- Net income: -$8.91M (prior year $247.00K) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.03 (prior year $0.00)
Aug 5, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 1, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Ostrowski Erik sold 56,019 shares at $1.11 (≈$62.18K) on Jun 29, 2026
- Ostrowski Erik sold 56,019 shares at $1.11 (≈$62.18K) on Jun 29, 2026
- Ostrowski Erik sold 56,019 shares at $1.11 (≈$62.18K) on Jun 29, 2026
- Ostrowski Erik sold 56,019 shares at $1.11 (≈$62.18K) on Jun 29, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Jun 30, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Jun 29, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Jun 22, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jun 22, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jun 22, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jun 22, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.07 — Reported shareholder vote results.
Things to know before you trade AKBA
- Last results release: Aug 5, 2026 (8-K Item 2.02). Previous ones: May 7, 2026, Feb 26, 2026, Jan 12, 2026. Based on that rhythm, the next report is likely around Nov 4, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.09% (largest 8.8%). That is a volatile stock.
- Liquidity: about 7.03M shares (≈$4.71M) trade per day on average.
- 52-week position: $0.67 vs a range of $0.67–$3.20 (0% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 4 open-market buys, 21 sales; latest: Erik Ostrowski sold 56,019 shares on Jun 29, 2026.
- Latest filings: 8-K Oct 14, 2026; 10-Q Aug 5, 2026; 8-K Aug 5, 2026.
- Share count: 277.11M shares outstanding (Jul 31, 2026), +4.5% vs a year earlier.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
AKBA market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 0.71 | 0.73 | 0.67 | 0.67 | 7.05M |
| Oct 15, 2026 | 0.70 | 0.73 | 0.69 | 0.70 | 8.92M |
| Oct 14, 2026 | 0.75 | 0.77 | 0.70 | 0.70 | 13.96M |
| Oct 13, 2026 | 0.80 | 0.81 | 0.77 | 0.77 | 6.50M |
| Oct 12, 2026 | 0.80 | 0.81 | 0.77 | 0.79 | 8.87M |
| Oct 9, 2026 | 0.82 | 0.83 | 0.80 | 0.80 | 6.09M |
| Oct 8, 2026 | 0.85 | 0.87 | 0.81 | 0.81 | 7.45M |
| Oct 7, 2026 | 0.86 | 0.89 | 0.86 | 0.87 | 9.16M |
| Oct 6, 2026 | 0.90 | 0.91 | 0.88 | 0.88 | 6.18M |
| Oct 5, 2026 | 0.87 | 0.92 | 0.85 | 0.91 | 7.50M |
| Oct 2, 2026 | 0.89 | 0.89 | 0.84 | 0.87 | 7.11M |
| Oct 1, 2026 | 0.92 | 0.92 | 0.87 | 0.87 | 4.51M |
| Sep 30, 2026 | 0.89 | 0.93 | 0.87 | 0.92 | 10.83M |
| Sep 29, 2026 | 0.90 | 0.90 | 0.87 | 0.89 | 3.45M |
| Sep 28, 2026 | 0.89 | 0.90 | 0.88 | 0.89 | 3.40M |
| Sep 25, 2026 | 0.92 | 0.93 | 0.89 | 0.90 | 4.37M |
| Sep 24, 2026 | 0.92 | 0.95 | 0.91 | 0.92 | 3.73M |
| Sep 23, 2026 | 0.99 | 0.99 | 0.93 | 0.93 | 5.39M |
| Sep 22, 2026 | 0.95 | 1.00 | 0.94 | 0.98 | 5.11M |
| Sep 21, 2026 | 0.93 | 0.95 | 0.92 | 0.94 | 11.09M |
About Akebia Therapeutics
Akebia Therapeutics (AKBA) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in WALTHAM, MA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1517022.
AKBA board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Adrian Adams | Director | Jun 22, 2026 |
| John P. Butler | CEO and President | Aug 10, 2026 |
| Ron Frieson | Director | Jun 22, 2026 |
| Michael W Rogers | Director | Jun 22, 2026 |
| Cynthia Smith | Director | Jun 22, 2026 |
| Philip J. Vickers | Director | Apr 3, 2026 |
| Myles Wolf | Director | Jun 22, 2026 |
| Leanne M Zumwalt | Director | Jun 22, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Steven Keith Burke | SVP, Chief Medical Officer | Feb 4, 2026 |
| John P. Butler | CEO and President | Aug 10, 2026 |
| Nicholas Grund | Chief Commercial Officer | Feb 4, 2026 |
| Richard C Malabre | SVP, Chief Accounting Officer | Feb 4, 2026 |
| Erik Ostrowski | SVP, CFO, CBO & Treasurer | Jul 1, 2026 |
| Carolyn M. Rucci | SVP, Chief Legal Officer | Feb 4, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 29, 2026 | Erik Ostrowski | Sale | 56,019 | $1.11 |
| Jun 29, 2026 | Erik Ostrowski | Sale | 56,019 | $1.11 |
| Jun 29, 2026 | Erik Ostrowski | Sale | 56,019 | $1.11 |
| Jun 29, 2026 | Erik Ostrowski | Sale | 56,019 | $1.11 |
| Mar 4, 2026 | John P. Butler | Buy | 69,270 | $1.25 |
| Mar 4, 2026 | John P. Butler | Buy | 69,270 | $1.25 |
| Mar 4, 2026 | John P. Butler | Buy | 69,270 | $1.25 |
| Mar 4, 2026 | John P. Butler | Buy | 69,270 | $1.25 |
| Feb 2, 2026 | Carolyn M. Rucci | Sale | 16,846 | $1.39 |
| Feb 2, 2026 | Carolyn M. Rucci | Sale | 25,382 | $1.39 |
| Feb 2, 2026 | Carolyn M. Rucci | Sale | 27,544 | $1.39 |
| Feb 2, 2026 | Carolyn M. Rucci | Sale | 16,846 | $1.39 |
| Feb 2, 2026 | Carolyn M. Rucci | Sale | 25,382 | $1.39 |
| Feb 2, 2026 | Carolyn M. Rucci | Sale | 27,544 | $1.39 |
| Feb 2, 2026 | Carolyn M. Rucci | Sale | 16,846 | $1.39 |
AKBA financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $236.20M | $-5.34M | -0.02 | $67.99M |
| Dec 31, 2024 | $160.18M | $-69.41M | -0.33 | $-40.66M |
| Dec 31, 2023 | $194.62M | $-51.92M | -0.28 | $-23.38M |
| Dec 31, 2022 | $292.48M | $-94.23M | -0.52 | $-73.15M |
| Dec 31, 2021 | $213.58M | $-282.84M | -1.70 | $-252.97M |
Latest balance sheet: total assets $349.66M, total liabilities $324.64M, cash $155.55M (as of Jun 30, 2026).
AKBA earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 5, 2026 | 8-K Item 2.02 (results) | $1.29 |
| May 7, 2026 | 8-K Item 2.02 (results) | $1.18 |
| Feb 26, 2026 | 8-K Item 2.02 (results) | $1.32 |
| Jan 12, 2026 | 8-K Item 2.02 (results) | $1.40 |
| Nov 10, 2025 | 8-K Item 2.02 (results) | $1.67 |
| Aug 7, 2025 | 8-K Item 2.02 (results) | $3.01 |
| May 8, 2025 | 8-K Item 2.02 (results) | $2.62 |
| Mar 13, 2025 | 8-K Item 2.02 (results) | $1.69 |
| Nov 7, 2024 | 8-K Item 2.02 (results) | $1.87 |
| Aug 8, 2024 | 8-K Item 2.02 (results) | — |
| May 9, 2024 | 8-K Item 2.02 (results) | — |
| Mar 14, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on AKBA
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.